The Zepbound situation is worth a second look
What the Evidence Shows and What It Does Not MedicalDaily Evidence Check Study type: Phase 2b randomized clinical trial Participants: 272 adults with type 2 diabetes, average age 50.8, from 37 sites in China Published in: Annals of Internal Medicine , June 30, 2026 (DOI: 10.7326/ANNALS-25-04623) What it found: Biweekly bofanglutide produced HbA1c reductions and weight loss comparable to weekly semaglutide in Chinese patients with type 2 diabetes What it did not prove: The trial was not conducted in U.S
McGehee WG, Klotz TA, Epstein DJ, Rapaport SI
AOD-9604 is not a nervous system stimulant (like caffeine or other thermogenics)
As highlighted by specialists in the area, incorporating this medication into a tailored health management plan, supported by continuous guidance, can empower women to regain their well-being during these critical life phases